Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension

Hypertension Clinical Trial

— dysh  

Official title:

Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01455714
• Other study ID #: RNN/446/10/KB
• Status: Not yet recruiting
• Phase: N/A
• First received: September 21, 2011
• Last updated: October 19, 2011
• Start date: September 2012
• Est. completion date: September 2014

Study information

• Verified date: October 2011
• Source: Medical Universtity of Lodz
• Contact: Agata Bielecka-Dabrowa, PhD
• Phone: +48606644176
• Email: agatbiel7[@]poczta.onet.pl
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Finding early predictors of myocardial in patients with hypertension

1. Scientific objective The study objective is to clarify the grounds of heart exertional dyspnoea stenocardial pain in patients with well-controlled stage I or II hypertension according to ESH (European Society of Hypertension), without changes in epicardial coronary arteries in coronary angiography and normal resting echocardiography result, and to assess of potential early markers of heart hypertrophy and failure in patients with hypertension.

Characteristics of the final result The study is to allow for identification of patients with hypertension, in whom an early introduction of pharmacological treatment of heart failure should be considered. Evaluation in the detection of asymptomatic myocardial dysfunction will include potential heart failure markers such as: cardiotrophin 1, cystatin C, serum syndecan-4, collagen III N-terminal propetide [PIIINP], MMP-2, MMP-7, MMP-8, MMP-9 and NT-proBNP, modern echocardiography methods and magnetic resonance imaging in order to increase the effectiveness of prevention, diagnosis and treatment optimalization.

2. Project significance Prognosis in heart failure is very serious. It is similar or worse than in advanced cancer. These data indicate an extreme importance of the optimal early causal treatment of hypertension and symptomatic treatment of heart failure early stage in order to prevent the development advanced form of the disease, which has bad prognosis. In clinical practice, patients with well-controlled hypertension often report exercise limitation, exertional dyspnea and/or stenocardial pain which is not reflected in a standard resting echocardiography (normal result), without coronary artery disease data in electrocardiographic stress test and without change in epicardial coronary vessels in coronary angiography. The study is designed to establish the panel of diagnostic tests in patients with hypertension and exertional dyspnoea only, which will allow for early detection of abnormalities (before symptoms occur) and the start of the optimal treatment for these patients. Unfortunately, still too small percentage of patients receives full pharmacotherapy, hence the authors of the latest guidelines of procedure in heart failure and hypertension put great emphasis on this aspect. Optimal management may prevent the progression of these patients in stage C heart failure, and thus bring tangible benefits not only the patients themselves but also, by reducing the number of costly hospitalizations, significantly reduce health care costs. The number of hospitalizations for heart failure in Poland is estimated at 100 000 per year, and hospitalization costs exceed 70% of the total costs associated with the treatment of heart failure. The issue of exertional dyspnoea and overt heart failure in patients with hypertension and normal results of resting echocardiography is a new problem, both in Poland and in the world.

So far, there are no treatment recommendations for this group of patients. Material and study plan 120 persons (age 40-60 years old) will be included in the study, patients with stage I or II primary hypertension according to the European Society of Hypertension: Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure

In group B (patients with exertional dyspnea/stenocardia) we will include only patients who have undergone contrast coronary angiography without any identified changes in the epicardial coronary arteries, which will facilitate answering the presented purpose of research. Patients in groups A and B with normal resting echocardiography and treated with a maximum of 2 antihypertensive drugs (an ACE inhibitor or a sartan as therapy base), according to the following regimen:

ACEI/ARB + diuretic ACEI/ARB + calcium channel antagonist Group C - treatment in accordance with the standards for heart failure. Each patient will be informed about the objectives of the study and give written consent to participate.

After signing informed consent patients will have performed the following tests:

• Interview and documentation analysis,

• Physical examination,

• Electrocardiogram,

• 24-hour blood pressure monitoring (ABPM),

• 24-hour EKG recording,

• Echocardiography at rest and during submaxinal exercise on a bicycle ergometer,

• Flow-mediated dilatation (FMD),

• Cardiac magnetic resonance imaging,

• Standard labolatory parameters,

• Levels of markers: cystatin C, cardiotrophin-1, metaloproteinases: MMP-2, MMP-7, MMP-8, MMP-9, Procollagen III N-Terminal Propeptide (PIIINP), Syndecan 4 (SDC4) and NT-proBNP Each patient will be informed about the objectives of the study and give written consent to participate.

Description:

The concept and plan of study

1. The attempt to clarify the grounds of heart exertional dyspnoea stenocardial pain in patients with well-controlled stage I or II hypertension according to ESH (European Society of Hypertension), without changes in epicardial coronary arteries in coronary angiography and normal resting echocardiography.

2. MRI evaluation of coronary microcirculation and endothelial function assessed by flow-dependent vasodilation in hypertensive patients with and without heart failure symptoms.

3. Comparison of modern echocardiographic methods and magnetic resonance imaging in the diagnosis of hypertensive patients with and without overt heart failure.

4. Cystatin C as a new marker of organ damage in patients with hypertension and comparison of cystatin C with GFR assessed by MDRD and Cockcroft-Gault creatinine clearance on as renal function assessment indicators in patients with hypertension.

5. Evaluation of new markers - cardiotrophin 1 and cystatin C, serum syndecan-4, collagen III N-terminal propetide [PIIINP], MMP-2, MMP-7,MMP-8, MMP-9 and NT-proBNP in the early diagnosis of heart failure.

6. Potential markers of heart failure, modern echocardiography methods and magnetic resonance imaging in the detection of asymptomatic myocardial dysfunction in order to increase the effectiveness of prevention and treatment.

7. Searching for the relationship between the type of hypertension (dipper or non-dipper) and the development of heart failure symptoms, and whether there are differences between the echocardiographic images of these patients?

8. Selection of patients with hypertension, in whom an early introduction of pharmacological treatment of heart failure should be considered.

9. The study will also help answer the following questions: (a) Which parameters best assess the overall cardiovascular risk? and (b) When the treatment of heart failure in patients with hypertension should start.

The measurable effect of this research besides cognitive is to the possibility of reducing the proportion of patients who come to overt heart failure connected with hypertension through the optimization of preventive, diagnostic methods and to determine the optimum treatment in these patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: September 2014
• Est. primary completion date: December 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 40 Years to 60 Years

Eligibility

Inclusion Criteria:

• 120 persons (age 40-60 years old) will be included in the study, patients with stage I or II primary hypertension according to the European Society of Hypertension

Exclusion Criteria:

Following patients will be excluded from the study:

• with coronary artery disease or a history of coronary artery disease

• with unstable hypertension

• with a positive stress test

• with NYHA class III-IV heart failure

• after percutaneous or surgical revascularization

• with diabetes

• with GFR < 60

• with hyperthyroidism and hypothyroidism

• active smokers

• with an implanted pacemaker

• with hip, knee endoprosthesis

• with claustrophobia

• with obesity level II and III

• with ECG-arrhythmia

• pregnant and lactating

• with congenital heart disease

• with hemodynamically significant acquired heart defects

• with cardiomyopathies

• with cancer

• with anemia

• abusing alcohol or drugs

• with chronic inflammatory and other diseases

• or who have not given their informed consent to participate in the study

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Hypertension

Locations

Country	Name	City	State
Poland	Department of Hypertension MU of Lodz	Lodz

Sponsors (1)

Lead Sponsor	Collaborator
Medical Universtity of Lodz

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in levels of biomarkers	Levels of markers: cystatin C, cardiotrophin-1, metaloproteinases: MMP-2, MMP-7, MMP-8, MMP-9, Procollagen III N-Terminal Propeptide (PIIINP), Syndecan 4 (SDC4) and NT-proBNP	two years	No
Primary	echocardiographical parameters	Echocardiography at rest and during submaxinal exercise on a bicycle ergometer	two years	Yes
Primary	assessment of perfusion and endothelium function	Flow-mediated dilatation (FMD),; Cardiac magnetic resonance imaging,	two years	Yes
Secondary	mortality		two years	Yes
Secondary	exertional dyspnoea		two years	No
Secondary	heart failure aggravation		two years	Yes